The mitochondria hypothesis is moving from fringe to framework in cancer and mental illness research
For decades, cancer and psychiatric disease have been explained primarily through the lens of genetic mutation and neurotransmitter imbalance. A growing body of evidence points elsewhere: to the mitochondria, and to the possibility that both classes of disease are, at their root, disorders of energy.
The standard account of cancer begins with a broken gene. A mutation accumulates, a cell loses control of its own replication, and a tumor follows. Thomas Seyfried, a cancer biologist, argues this account has the causation reversed. Every cancer cell his team has examined shows defects in the number, structure, and function of mitochondria. The genetic mutations associated with cancer, he contends, are not 100 percent penetrant, which means they are secondary risk factors rather than primary causes. The origin of the disease, in his framing, resides in the mitochondria.
Martin Picard, a mitochondrial psychobiologist, arrives at a compatible position from a different direction. Where Seyfried focuses on cancer, Picard has extended the metabolic framing into psychiatry. His view is that changes in metabolism and in the flow of electrons through the mitochondrial circuitry can drive the emergence of a new cancer cell. But the same energetic logic, he argues, may apply to the mind. Injecting lactate, a signal of energetic stress, can trigger a panic attack. People with elevated GDF-15, a mitochondrial stress marker, are more likely to develop bipolar disorder, depression, or schizophrenia. If those associations hold under further scrutiny, several major psychiatric conditions may be, in part, disorders of cellular energy rather than disorders of chemistry alone.
The picture Seyfried draws of a cancer cell under the microscope is striking. The mitochondria in such cells are often hollow: the internal membrane structures, called cristae, are missing or deformed. He describes these as ghost mitochondria, a shell with nothing functional inside. Because the mitochondria are too damaged to burn fatty acids or ketone bodies, cancer cells are locked into dependence on glucose and glutamine. They cannot make the metabolic switch that healthy cells can. This dependency, Seyfried argues, is not a side effect of cancer but a defining feature of it. Oxygen in such cells is used not to produce meaningful amounts of ATP but to generate reactive oxygen species that further damage DNA, producing the mutations that the genetic theory treats as the origin point.
Seyfried also identifies intermittent hypoxia as a likely upstream trigger: repeated cycles of low oxygen damage the efficiency of oxidative phosphorylation, pushing cells toward compensatory fermentation. That is, the metabolic shift precedes and enables the cancerous state. A minority of oncologists, he notes, are beginning to apply this logic clinically, using ketogenic diets and fasting protocols to protect healthy cells and sensitize tumors before administering lower, more targeted doses of chemotherapy.
The cancer community used to think that the main driver for cancer was genetic mutations but there's an emerging perspective that changes in metabolism changes in the way electrons flow through this energetic circuitry through the mitochondria can drive the instance of a of a new cancer cell Martin Picard
The connection to lifespan is an extension of the same framework. Seyfried argues that the varying lifespans of different species, from mice at roughly two and a half years to elephants and humans at far longer, are all determined by the condition and effective expiration date of their mitochondria. That is a large claim, but it fits the broader pattern: if mitochondrial integrity governs both cellular energy production and the fidelity of cellular replication, it is not a stretch to place it at the center of aging as well.
Tim Ferriss has noted, in a related vein, that vascular dementia and mitochondrial dysfunction may be the real drivers of Alzheimer’s disease rather than amyloid beta accumulation, the target that has consumed the bulk of Alzheimer’s drug development investment. That framing aligns with the growing skepticism, now well documented in the research literature, about whether clearing amyloid plaques translates into meaningful clinical benefit.
Matt Walker’s observation sits at the edge of this territory. No psychiatric condition, he has noted, has been found in which sleep is normal. Sleep is one of the most metabolically intensive states a body enters. The finding does not establish causation in any direction, but it adds another data point to the pattern: disrupted energy regulation and psychiatric disease are found together with a consistency that symptom-focused diagnostic models have not fully explained.
A 2025 peer-reviewed analysis published in MDPI and a 2026 review in Frontiers in Oncology both engage seriously with the mitochondrial origin hypothesis, the latter noting that mutation-based models do not fully account for why normal tissues tolerate large mutational burdens or why some tumors lack recurrent driver mutations. The academic reception is not yet a consensus, but it is no longer a dismissal. What Seyfried and Picard are describing is not a rejection of genetics but a reordering of causation: metabolism first, mutation second. If that reordering survives further scrutiny, the implications for how cancer and psychiatric disease are treated, not just classified, will be substantial.